About: Performance of Abbott ID NOW COVID-19 rapid nucleic acid amplification test in nasopharyngeal swabs transported in viral media and dry nasal swabs, in a New York City academic institution

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Performance of Abbott ID NOW COVID-19 rapid nucleic acid amplification test in nasopharyngeal swabs transported in viral media and dry nasal swabs, in a New York City academic institution Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Performance of Abbott ID NOW COVID-19 rapid nucleic acid amplification test in nasopharyngeal swabs transported in viral media and dry nasal swabs, in a New York City academic institution
Creator	Aguero-Rosenfeld, Maria Atie, Onome Baptiste, Patricia Basu, Atreyee Burns, Jacquelyn Clouden, Lauryn David, Roselle Garcia, Jason Inglima, Kenneth Keida, Robin See, Benjamin Tiarsmith, Jennifer Woo, Kar-Mun Yurasits, Lauren Zinger, Tatyana
Source	BioRxiv
abstract	The recent emergence of the SARS-CoV-2 pandemic has posed formidable challenges for clinical laboratories seeking reliable laboratory diagnostic confirmation. The swift advance of the crisis in the United States has led to Emergency Use Authorization (EUA) facilitating the availability of molecular diagnostic assays without the more rigorous examination to which tests are normally subjected prior to FDA approval. Our laboratory currently uses two real time RT-PCR platforms, the Roche Cobas SARS-CoV2 and the Cepheid Xpert Xpress SARS-CoV-2. Both platforms demonstrate comparable performance; however, the run times for each assay are 3.5 hours and 45 minutes, respectively. In search for a platform with shorter turnaround time, we sought to evaluate the recently released Abbott ID NOW COVID-19 assay which is capable of producing positive results in as little as 5 minutes. We present here the results of comparisons between Abbott ID NOW COVID-19 and Cepheid Xpert Xpress SARS-CoV-2 using nasopharyngeal swabs transported in viral transport media and comparisons between Abbott ID NOW COVID-19 and Cepheid Xpert Xpress SARS-CoV-2 using nasopharyngeal swabs transported in viral transport media for Cepheid and dry nasal swabs for Abbott ID NOW. Regardless of method of collection and sample type, Abbott ID NOW COVID-19 had negative results in a third of the samples that tested positive by Cepheid Xpert Xpress when using nasopharyngeal swabs in viral transport media and 45% when using dry nasal swabs.
has issue date	2020-05-29(xsd:dateTime)
bibo:doi	10.1101/2020.05.11.089896
has license	biorxiv
sha1sum (hex)	0063a35f5296d99290afa742f6b2b8eccc1788ff
schema:url	https://doi.org/10.1101/2020.05.11.089896
resource representing a document's title	Performance of Abbott ID NOW COVID-19 rapid nucleic acid amplification test in nasopharyngeal swabs transported in viral media and dry nasal swabs, in a New York City academic institution
schema:publication	bioRxiv
resource representing a document's body	covid:0063a35f5296d99290afa742f6b2b8eccc1788ff#body_text
is schema:about of	named entity 'SARS-CoV-2' named entity 'Running' named entity 'FDA APPROVAL' named entity 'LED' named entity 'LABORATORY' named entity 'XPRESS' named entity 'RELIABLE' named entity 'PANDEMIC' named entity 'CONFIRMATION' covid:arg/0063a35f5296d99290afa742f6b2b8eccc1788ff named entity 'GeneXpert' named entity 'SARS-CoV-2' named entity 'Evidence-Based Medicine' named entity 'nasopharyngeal' named entity 'nasopharyngeal swabs' named entity 'Puritan' named entity 'Emergency Department' named entity 'SARS-CoV-2' named entity 'NYU' named entity 'SARS-CoV-2' named entity 'Transport Medium' named entity 'tested positive' named entity 'Emergency Department' named entity 'package insert' named entity 'viral load' named entity 'COVID-19' named entity 'RNA' named entity 'reference method' named entity 'VTM' named entity 'Xpert Xpress' named entity 'asymptomatic' named entity '19.3' named entity 'seeking' named entity 'viral media' named entity 'laboratory' named entity 'medical' named entity 'New York City' named entity 'Xpert Xpress' named entity 'SARS-CoV-2' named entity 'United States' named entity 'Emergency Medicine' named entity 'nasopharyngeal swabs' named entity 'Xpert Xpress' named entity 'COVID-19 disease' named entity 'SARS-CoV-2' named entity 'POC' named entity 'Medical Products' named entity 'package insert' named entity 'PCR' named entity 'viral load' named entity 'RNA' named entity 'VTM' named entity 'Xpert Xpress' named entity 'Xpert Xpress' named entity 'Tisch Hospital' named entity 'SARS-CoV-2' named entity '13 minutes' named entity 'RNA' named entity 'Cobas' named entity 'real-time RT-PCR' named entity 'LOD' named entity 'Xpert Xpress' named entity 'Xpert Xpress' named entity 'VTM' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'VTM' named entity 'EUA' named entity 'nucleocapsid' named entity 'RT-PCR'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software